Related Experiment Videos
Suicide gene therapy for human oral squamous cell carcinoma cell lines with adeno-associated virus vector
1Department of Oral and Maxillofacial Surgery, Nagoya University Graduate School of Medicine, 65 Tsuruma-cho, Showa-ku, 466-8550, Nagoya, Japan.
Abstract:
The purpose of this study was to test the possibility of gene transfer as a new therapy for oral cancer. Adeno-associated virus (AAV) has already been used in the fields of cystic fibrosis and Parkinson's disease as a potential vector for gene therapy because of its wide host range, high transduction efficiency, and lack of cytopathogenicity. Four human oral squamous cell carcinoma cell lines were transduced with an AAV vector containing the beta-galactosidase gene (AAVlacZ) in vitro. Gene transduction efficiency was from 20 to 50% at a multiplicity of infection (MOI; for the purposes of this study the number of vector genomes per target cell) of 1x10(3), and nearly 100% of each cell line were transduced at an MOI of 1x10(4). Next, four cell lines were transduced with an AAV vector containing the herpes simplex virus thymidine kinase (HSVtk) gene, which sensitizes transduced cells to ganciclovir (GCV). Subsequent administration of GCV resulted in nearly 100% tumor cell killing at an MOI of 1x10(4) and from 70 to 80% tumor cell killing at an MOI of 1x10(3). These results suggest that AAV-mediated gene transfer of HSVtk and administration of GCV has potential as a new therapy for oral squamous cell carcinoma.
Insights
Gene transfer using adeno-associated virus (AAV) shows promise for oral cancer. This gene therapy approach, involving the herpes simplex virus thymidine kinase (HSVtk) gene and ganciclovir (GCV), effectively killed oral cancer cells in vitro.
Area of Science:
- Oncology
- Gene Therapy
- Virology
Background:
- Adeno-associated virus (AAV) is a promising vector for gene therapy due to its broad host range, high efficiency, and low toxicity.
- Previous applications of AAV include cystic fibrosis and Parkinson's disease.
- Oral squamous cell carcinoma (OSCC) is a significant global health concern requiring novel therapeutic strategies.
Purpose of the Study:
- To evaluate the potential of adeno-associated virus (AAV)-mediated gene transfer as a novel therapeutic approach for oral cancer.
- To assess the efficacy of AAV vectors carrying specific genes in oral cancer cell lines.
- To determine the optimal conditions for gene transduction and subsequent cell killing.
Main Methods:
- In vitro transduction of four human oral squamous cell carcinoma cell lines using AAV vectors.
- Utilized AAV vectors containing the beta-galactosidase gene (AAVlacZ) to determine transduction efficiency at varying multiplicities of infection (MOI).
- Employed AAV vectors carrying the herpes simplex virus thymidine kinase (HSVtk) gene, followed by ganciclovir (GCV) administration to induce tumor cell death.
Main Results:
- Transduction efficiency of AAVlacZ ranged from 20-50% at an MOI of 1x10^3 and reached nearly 100% at an MOI of 1x10^4.
- AAV-mediated transfer of the HSVtk gene followed by ganciclovir treatment resulted in 70-80% tumor cell killing at an MOI of 1x10^3 and nearly 100% killing at an MOI of 1x10^4.
- Demonstrated significant tumor cell killing in all tested oral cancer cell lines.
Conclusions:
- AAV-mediated gene transfer of the HSVtk gene, combined with ganciclovir administration, is a potent strategy for eradicating oral squamous cell carcinoma cells in vitro.
- This gene therapy approach holds significant potential as a new treatment modality for oral cancer.
- Further research is warranted to translate these findings into clinical applications for oral cancer patients.